The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Recent advancements in lung cancer treatment
Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, Leicester, UK, provides an overview of the latest developments in adjuvant and neoadjuvant therapies for lung cancer. Osimertinib is a promising therapy for patients with EFGR-mutated lung cancer post-surgery, and adjuvant atezolizumab has demonstrated efficacy in the perioperative setting, making surgery worthwhile for patients. Neoadjuvant therapy is an additional area of interest, where certain groups of patients will benefit from pre-operative treatment. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
